Hagit Eldar-Finkelman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6444381/publications.pdf

Version: 2024-02-01

58 papers	8,701 citations	101384 36 h-index	143772 57 g-index
58 all docs	58 docs citations	58 times ranked	18139 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Glycogen synthase kinase 3: an emerging therapeutic target. Trends in Molecular Medicine, 2002, 8, 126-132.	3.5	380
3	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Frontiers in Molecular Neuroscience, 2011, 4, 32.	1.4	274
4	Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on Î²-catenin in mouse hippocampus. Biological Psychiatry, 2004, 55, 781-784.	0.7	269
5	Leptin Induces Insulin-like Signaling That Antagonizes cAMP Elevation by Glucagon in Hepatocytes. Journal of Biological Chemistry, 2000, 275, 11348-11354.	1.6	214
6	Inactivation of Glycogen Synthase Kinase-3 by Epidermal Growth Factor Is Mediated by Mitogen-activated Protein Kinase/p90 Ribosomal Protein S6 Kinase Signaling Pathway in NIH/3T3 Cells. Journal of Biological Chemistry, 1995, 270, 987-990.	1.6	201
7	Inhibition of Glycogen Synthase Kinase-3 Ameliorates Î²-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model. Journal of Biological Chemistry, 2013, 288, 1295-1306.	1.6	193
8	Increased glucose uptake promotes oxidative stress and PKC-Î´ activation in adipocytes of obese, insulin-resistant mice. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E295-E302.	1.8	164
9	Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling. Journal of Biological Chemistry, 2005, 280, 4422-4428.	1.6	145
10	Inhibition of glycogen synthase kinase-3Î² by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications, 2002, 295, 102-106.	1.0	142
11	Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 974-980.	1.3	136
12	PKC-Î´-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E405-E411.	1.8	107
13	Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 17-24.	1.3	104
14	Role of glycogen synthase kinase-3Î²Â in early depressive behavior induced by mild traumatic brain injury. Molecular and Cellular Neurosciences, 2007, 34, 571-577.	1.0	104
15	The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opinion on Therapeutic Targets, 2002, 6, 555-561.	1.5	89
16	Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene, 2015, 34, 4613-4623.	2.6	81
17	Nuclear GSK-3Î² inhibits the canonical Wnt signalling pathway in a Î²-catenin phosphorylation-independent manner. Oncogene, 2008, 27, 3546-3555.	2.6	80
18	Peptide Inhibitors Targeting Protein Kinases. Current Pharmaceutical Design, 2009, 15, 2463-2470.	0.9	77

#	Article	IF	Citations
19	Glycogen synthase kinase 3Î² mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. Journal of Endocrinology, 2010, 206, 171-181.	1.2	77
20	Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. Journal of Immunology, 2013, 190, 5000-5011.	0.4	71
21	Lithium-Mediated Phosphorylation of Glycogen Synthase Kinase-3b Involves PI3 Kinase-Dependent Activation of Protein Kinase C-Î±. Journal of Molecular Neuroscience, 2004, 24, 237-246.	1.1	62
22	Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E307-E315.	1.8	62
23	Regulation of Ribosomal S6 Protein Kinase-p90^{<i>rsk</i>}, Glycogen Synthase Kinase 3, and Î²-Catenin in Early <i>Xenopus</i> Development. Molecular and Cellular Biology, 1999, 19, 1427-1437.	1.1	54
24	A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Science Signaling, 2016, 9, ra110.	1.6	53
25	Substrate Competitive GSK-3 Inhibitors strategy and Implications. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 598-603.	1.1	50
26	Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration. Cells, 2021, 10, 262.	1.8	48
27	Identification of Novel Glycogen Synthase Kinase-3Î² Substrate-interacting Residues Suggests a Common Mechanism for Substrate Recognition. Journal of Biological Chemistry, 2006, 281, 30621-30630.	1.6	47
28	Selective loss of glycogen synthase kinase-3Î± in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. FEBS Letters, 2011, 585, 1158-1162.	1.3	46
29	Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. Expert Opinion on Investigational Drugs, 2003, 12, 1511-1519.	1.9	45
30	Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3Î±. Journal of Medicinal Chemistry, 2012, 55, 4407-4424.	2.9	45
31	Peptides Targeting Protein Kinases: Strategies and Implications. Physiology, 2006, 21, 411-418.	1.6	43
32	GSK3Î² and Î²-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer. Neoplasia, 2010, 12, 357-365.	2.3	43
33	Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid Î²-peptide. Journal of Neurochemistry, 2011, 116, 522-529.	2.1	41
34	Distinct Molecular Regulation of Glycogen Synthase Kinase-3Î± Isozyme Controlled by Its N-terminal Region. Journal of Biological Chemistry, 2011, 286, 13470-13480.	1.6	41
35	Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-<i>e</i>]pyrrolo[3,4-<i>g</i>]indolizine-4,6(1<i>H</i>,5<i>H</i>)-diones as New Glycogen Synthase Kinase-3Î² Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 10066-10078.	2.9	39
36	The SIL Gene Is Essential for Mitotic Entry and Survival of Cancer Cells. Cancer Research, 2007, 67, 4022-4027.	0.4	38

#	Article	IF	Citations
37	GSK-3 inhibition: Achieving moderate efficacy with high selectivity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1410-1414.	1.1	37
38	Structure-based optimization of oxadiazole-based GSK-3 inhibitors. European Journal of Medicinal Chemistry, 2013, 61, 26-40.	2.6	35
39	Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward. Frontiers in Molecular Neuroscience, 2021, 14, 792364.	1.4	33
40	Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase CÎ²II in the diabetic fat tissue. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E1169-E1177.	1.8	25
41	Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3Î² and the Refinement of a Competitive Inhibitor. Journal of Molecular Biology, 2011, 408, 366-378.	2.0	22
42	Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: An fast and atom efficient access to 1-aryl-3-benzylureas. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5610-5615.	1.0	22
43	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight, 2017, 2, e91782.	2.3	22
44	New Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3Î². Journal of Molecular Biology, 2008, 383, 999-1007.	2.0	21
45	Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Molecular and Cellular Neurosciences, 2010, 45, 449-455.	1.0	18
46	GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. Cellular Signalling, 2020, 71, 109597.	1.7	16
47	Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 49-54.	2.5	15
48	Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. International Journal of Molecular Sciences, 2020, 21, 8709.	1.8	14
49	Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease. Neurobiology of Disease, 2021, 154, 105336.	2.1	14
50	Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. World Journal of Biological Psychiatry, 2017, 18, 445-456.	1.3	11
51	Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases. Current Pharmaceutical Design, 2012, 18, 2914-2920.	0.9	10
52	GSK-3Î² Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds. Brain, Behavior and Evolution, 2015, 85, 233-244.	0.9	7
53	GSK-3 and lysosomes meet in Alzheimerâ€™s disease. Communicative and Integrative Biology, 2013, 6, e25179.	0.6	6
54	<i>Science Signaling</i> Podcast for 15 November 2016: A new type of kinase inhibitor. Science Signaling, 2016, 9, c22.	1.6	2

#	Article	IF	Citations
55	Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy. Cells, 2022, 11, 1618.	1.8	2
56	Profile. Drug Discovery Today, 2001, 6, 1072-1073.	3.2	1
57	Novel Modality of GSK-3 Inhibition For Treating Neurodegeneration. Journal of Neurology and Neuromedicine, 2018, 3, 5-7.	0.9	1
58	GSK-3Î² Inhibition in Birds Affects Social Behavior and Increases Motor Activity. Frontiers in Physiology, 2022, 13, 881174.	1.3	1